Biopharma buffers are solutions used for maintaining a stable pH during various biopharmaceutical processes such as cell cultivation, fermentation, purification and chromatography. They help provide optimal conditions for cell growth and metabolic activities. The global biopharma buffer market is estimated to be valued at US$ 4.24 Bn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2024-2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Adoption of advanced technologies is one of the key trends driving the growth of the biopharma buffer market. Various biopharmaceutical companies are increasingly adopting advanced technologies such as automated liquid handling systems, robotic technologies, and pre-formulated chromatography buffers to streamline their production processes. These new technologies help improve consistency, reduce variability, and minimize operational costs. They also help enhance buffer preparation, storage, and end-use accuracy. Growing investment in R&D and focus on developing advanced technologies is expected to propel the biopharma buffer market during the forecast period.
Segment Analysis
The global biopharma buffer market is segmented based on product types, application, end user, and geography. Based on product types, the market is further segmented into disodium hydrogen phosphate, potassium dihydrogen phosphate, sodium chloride, calcium chloride and others. The disodium hydrogen phosphate segment held the dominant share of the market in 2021 owing to its use in various biopharmaceutical applications such as drug stability and lyophilization studies.
Key Takeaways
The Global Biopharma Buffer Market Share is expected to witness high growth during the forecast period 2024-2030.
Regional analysis: North America dominated the global biopharma buffer market in 2021 and is expected to continue its dominance during the forecast period. This is attributed to the presence of key pharmaceutical and biotechnology companies in the region and established healthcare infrastructure.
Key players: Key players operating in the biopharma buffer market are Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Novo Nordisk, Companion Medical Inc., Jiangsu Deflu Medical Device Co. Ltd., Medtronic PLC, Pendiq GmbH, Sanofi, Berlin Chemie Companion Medical Inc., Bigfoot Biomedical, Digital Medics Pty ltd, Eli Lilly and company, Ypsomed Holding AG, Diabnext Diamesco Co. Ltd. Sanofi dominated the market owing to its strong product portfolio and widespread distribution network.
Get More Insights Here
https://masstamilan.tv/printed-electronics-the-future-of-electronics-manufacturing/
https://www.ukwebwire.com/biopharma-buffer-market-size-share-growth-outlook-2023/
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Italiano
Russian
Romaian